Generation and in vitro testing of cancer immunotherapy from new subset of immune cells
2018
University College London Institute of Child Health, London, United Kingdom
Adoptive cellular therapy with T cells engineered to express chimeric antigen receptors (CARs) combines the antigen specificity of a monoclonal antibody with potent T cell activation, proliferative potential, and cytotoxic function. In the present study, the researchers sought to modify gamma delta T (gdT) lymphocytes to incorporate CARs to enhance their cytotoxicity while retaining their ability to migrate to tumors. The researchers transduced cells isolated from donors peripheral blood and tested them for cytotoxicity, migration capacity and antigen presentation using in vitro assays. The study shows that gamma delta T (gdT) including CAR have the capacity for migration and for uptake and cross-presentation of tumor-associated antigens, which was a potential advantage over conventional CAR-T cells, especially in the treatment of solid tumor.
Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation
Barry Flutter, John Anderson
Added on: 07-28-2021
[1] https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(17)30598-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001617305981%3Fshowall%3Dtrue[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
